AIA Group Ltd Sells 471 Shares of Inspire Medical Systems, Inc. (NYSE:INSP)

AIA Group Ltd reduced its holdings in Inspire Medical Systems, Inc. (NYSE:INSP) by 3.8% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 11,766 shares of the company’s stock after selling 471 shares during the period. AIA Group Ltd’s holdings in Inspire Medical Systems were worth $2,181,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Smartleaf Asset Management LLC raised its holdings in Inspire Medical Systems by 178.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 357 shares of the company’s stock valued at $66,000 after buying an additional 229 shares during the period. Merit Financial Group LLC bought a new position in Inspire Medical Systems during the fourth quarter valued at $313,000. Public Employees Retirement System of Ohio raised its stake in shares of Inspire Medical Systems by 9.4% in the third quarter. Public Employees Retirement System of Ohio now owns 36,361 shares of the company’s stock valued at $7,674,000 after acquiring an additional 3,125 shares during the period. Jennison Associates LLC bought a new stake in shares of Inspire Medical Systems in the 4th quarter worth about $8,821,000. Finally, Janney Montgomery Scott LLC boosted its stake in shares of Inspire Medical Systems by 248.5% during the 4th quarter. Janney Montgomery Scott LLC now owns 4,806 shares of the company’s stock worth $891,000 after purchasing an additional 3,427 shares during the period. 94.91% of the stock is currently owned by institutional investors.

Insider Activity

In other Inspire Medical Systems news, insider Randy Ban sold 25,584 shares of the firm’s stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $183.50, for a total value of $4,694,664.00. Following the completion of the sale, the insider now directly owns 7,259 shares in the company, valued at $1,332,026.50. This trade represents a 77.90 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CTO John Rondoni sold 583 shares of the company’s stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $170.49, for a total value of $99,395.67. Following the transaction, the chief technology officer now directly owns 10,424 shares in the company, valued at approximately $1,777,187.76. The trade was a 5.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 26,225 shares of company stock worth $4,806,530. 4.10% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on INSP shares. Morgan Stanley reduced their price objective on shares of Inspire Medical Systems from $230.00 to $220.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 11th. Piper Sandler reduced their price target on Inspire Medical Systems from $260.00 to $233.00 and set an “overweight” rating on the stock in a report on Monday, February 10th. Stifel Nicolaus dropped their price objective on Inspire Medical Systems from $200.00 to $190.00 and set a “hold” rating for the company in a report on Tuesday, January 21st. Royal Bank of Canada reiterated an “outperform” rating and issued a $260.00 target price on shares of Inspire Medical Systems in a research note on Tuesday, February 11th. Finally, KeyCorp reissued an “overweight” rating and set a $234.00 target price (down from $236.00) on shares of Inspire Medical Systems in a research note on Friday, January 24th. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $226.70.

Inspire Medical Systems Price Performance

Shares of Inspire Medical Systems stock opened at $159.60 on Tuesday. The stock has a market cap of $4.75 billion, a price-to-earnings ratio of 92.26, a PEG ratio of 2.86 and a beta of 1.48. The firm’s 50-day moving average is $178.78 and its two-hundred day moving average is $189.61. Inspire Medical Systems, Inc. has a 1 year low of $123.00 and a 1 year high of $257.40.

Inspire Medical Systems (NYSE:INSP) last released its quarterly earnings data on Monday, February 10th. The company reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.74 by $0.41. Inspire Medical Systems had a net margin of 6.67% and a return on equity of 8.19%. On average, equities analysts expect that Inspire Medical Systems, Inc. will post 2.16 earnings per share for the current year.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.